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Introduction
 
Diabetes mellitus is associated with the development of athero-
sclerosis [1]. Both macrovascular disease, such as acute coronary
syndrome, stroke and claudication, and microvascular disease,
such as diabetic nephropathy and retinopathy, are commoner
in diabetic than in non-diabetic populations and contribute
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Abstract
 
Aims
 
Type 2 diabetes is preceded by a symptom-free period of impaired glu-
cose tolerance (IGT). Pancreatic B-cell function decreases as glucose intolerance
develops. In many patients with IGT, fasting blood glucose is within normal
limits and hyperglycaemia occurs only postprandially. We examined whether
pancreatic B-cell function changes during acute hyperglycaemia induced by oral
glucose loading.
 
Methods
 
We calculated the insulinogenic index (I.I.) as an indicator of pancreatic
B-cell function and measured serum levels of thioredoxin, a marker of cellular
redox state, and 8-hydroxy-2
 
′
 
-deoxyguanosine (8-OHdG), a marker of oxidative
stress, during a 75-g oral glucose tolerance test (OGTT) in 45 subjects [24
patients with normal glucose tolerance (NGT), 14 with IGT and seven with
Type 2 diabetes].
 
Results
 
Thioredoxin levels decreased after glucose loading [66.1 
 
±
 
 23.7,
*59.3 
 
±
 
 22.4, *49.3 
 
±
 
 21.2 and *37.7 
 
±
 
 18.0 ng/ml, fasting (0 min) and at 30, 60
and 120 min, respectively; *
 
P <
 
 0.001 vs. fasting]. In contrast, concentrations of
8-OHdG peaked at 30  min and then gradually decreased (0.402 
 
±
 
 0.123,
*0.440 
 
±
 
 0.120, †0.362 
 
±
 
 0.119 and †0.355 
 
±
 
 0.131 ng/ml, *
 
P <
 
 0.05 vs. fasting,
†
 
P <
 
 0.01 vs. 30 min). The insulinogenic index correlated with the change in
thioredoxin levels (
 
r =
 
 0.34, 
 
P
 
 < 0.05). However, there was no relationship with
the change in 8-OHdG levels from 0 to 30 min.
 
Conclusions
 
Hyperglycaemia in response to oral glucose impairs pancreatic
B-cell function with decreasing thioredoxin levels. The augmented oxidative
stress induced by hyperglycaemia may affect the cellular redox state. These
findings strongly suggest that repeated postprandial hyperglycaemia may play
an important role in the development and progression of diabetes mellitus.
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to the morbidity and mortality associated with diabetes [1–3].
The predominant clinical form is Type 2 diabetes, which
accounts for > 90% of all cases [2,3]. Most Type 2 diabetes
is preceded by a symptom-free period of impaired glucose
tolerance (IGT), characterized by a response to oral glucose
loading that is abnormal but does not satisfy the criteria for
diabetes [1]. Patients with Type 2 diabetes show failure of
glucose-induced insulin secretion, which is characterized by a
decrease in the first phase of glucose-induced insulin secretion,
delayed hyperinsulinaemia and, latterly, failure of insulin
synthesis. Since Type 2 diabetes has a polygenetic background,
several factors may cause the failure of B cells. One possibility
is several types of stress, such as oxidative stress. Recently, we
and other investigators reported that acute hyperglycaemia
induces oxygen-derived free radicals [4–7], which are involved
in pancreatic B-cell dysfunction and apoptosis in an animal
model of Type 1 diabetes [8].
The redox state is finely tuned to preserve cellular homeos-
tasis through the expression and regulation of oxidant and
antioxidant enzymes. Mammalian cells have a complex net-
work of antioxidants such as catalase, superoxide dismutase
and glutathione peroxide to scavenge reactive oxygen species. In
addition to these enzymes, the members of the thiol-disulphide
oxidoreductase family act as cytoprotective antioxidants [9].
One of the most important thiol-disulphide oxidoreductases
is thioredoxin (TRX) [10].
The purpose of the present study was to examine the effect of
acute hyperglycaemia induced by oral glucose loading on pan-
creatic B-cell function. We further addressed the role of oxidative
stress in pancreatic B-cell function during oral glucose loading.
 
Patients and methods
 
Study subjects
 
The study group comprised 45 subjects (mean age 67 
 
±
 
 11 years)
who were admitted to our hospital for investigation of coronary
artery disease. None was known previously to have diabetes.
Fasting glucose levels were < 7.0 mmol/l and a 75-g oral glucose
tolerance test (OGTT) was done to examine risk factors for
coronary artery disease. Diabetes was diagnosed according to
World Health Organization criteria [2]. Twenty-four patients
had normal glucose tolerance (NGT), 14 had IGT and seven
had Type 2 diabetes mellitus (DM). Fourteen patients in the
NGT group, eight in the IGT group and five in the diabetes
group had ischaemic heart disease. The characteristics of the
patients are shown in Table 1. Written informed consent was
obtained from each patient before the study was commenced.
The procedures used in the study were approved by the ethics
committee at our institution.
 
Study design
 
The study was performed during a 75-g OGTT after a 12–14-h
fast. Blood samples were obtained in the fasting state, and 30,
60 and 120  min after the administration of a 75-g glucose
equivalent load (Trelan-G, Takeda, Japan). The plasma glucose
concentration was determined with an autoanalyser using a
glucose oxidase method. The serum insulin concentration was
measured by immunoradiometric assay using an antihuman in-
sulin antibody. Fasting serum total cholesterol and triglyceride
concentrations were measured enzymatically, and the serum
high-density lipoprotein cholesterol concentration was meas-
ured by heparin-Ca
 
2+
 
/Ni
 
2+
 
 precipitation [7,11]. The insulino-
genic index (I.I.) was calculated as the ratio of the increment of
insulin to that of plasma glucose 30 min after the glucose load
[(30 min  insulin 
 
−
 
  fasting insulin)/(30  min glucose 
 
−
 
 fasting
glucose)] [12,13].
Adaptation to stress evokes a variety of biological responses
in humans. TRX is an important constituent of cellular anti-
oxidant buffering systems that control the redox state of proteins,
which is released into the extracellular space [14]. We thus
measured the serum levels of TRX as a marker of the cytopro-
tective antioxidant system (ELISA kit; Fuji Rebio, Tokyo,
Japan) [14–17]. The detection limit of TRX was 2.0 ng/ml
and the intra- and interassay coefficients were 0.81–3.74% and
4.87–6.97%, respectively [14]. Plasma levels of 8-hydroxy-2
 
′
 
-
Table 1 Characteristics of study subjects
NGT (n = 24) IGT (n = 14) DM (n = 7) P-value
Age (years) 68 ± 12 64 ± 11 72 ± 3N S
Men/women (n) 10/14 10/4 2/5 NS
BMI (kg/m2) 23.7 ± 3.7 24.8 ± 4.7 25.7 ± 7.4 NS
HbA1c (%) 5.6 ± 0.4 5.8 ± 0.4 6.5 ± 0.5 < 0.01
FBG (mmol/l) 4.9 ± 0.4 5.4 ± 0.8 6.2 ± 0.7 < 0.01
SBP (mmHg) 133 ± 25 135 ± 25 135 ± 24 NS
DBP (mmHg) 79 ± 18 80 ± 12 70 ± 15 NS
Smoker/non-smoker 3/21 2/12 2/5 NS
Total cholesterol (mmol/l) 5.0 ± 0.90 5.5 ± 0.70 5.3 ± 0.62 NS
HDL-cholesterol (mmol/l) 1.29 ± 0.34 1.42 ± 0.47 1.55 ± 0.62 NS
Triglyceride (mmol/l) 3.2 ± 1.53 4.2 ± 2.02 3.1 ± 1.42 NS
BMI, Body mass index; DBP, diastolic blood pressure; DM, diabetes mellitus; FBG, fasting blood glucose; HDL, high-density lipoprotein; IGT, 
impaired glucose tolerance; NGT, normal glucose tolerance; SBP, systolic blood pressure. 
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deoxyguanosine (8-OHdG), a sensitive marker of oxidative
stress, were measured with enzyme-linked immunosorbent
assay (ELISA) (8-OHdG check; Japan Institute for the Control
of Ageing, Fukuorio, Shizuoka).
 
Statistical analysis
 
Comparisons of data between the three groups were performed
using one-way analysis of variance (
 
ANOVA
 
) followed by Bonfer-
roni’s multiple comparison test. The 
 
χ
 
2
 
 test was used to compare
gender and the prevalence of smokers. Changes in variables were
assessed by two-way 
 
ANOVA
 
 with repeated measures followed
by post hoc testing with Scheffe’s test. Correlations between the
insulinogenic index and plasma TRX concentrations, insulino-
genic index and plasma 8-OHdG concentrations were examined
with linear regression analysis. Statistical significance was
defined as 
 
P
 
 < 0.05.
 
Results
 
There were no differences in serum concentrations of total
cholesterol, low-density lipoprotein cholesterol, triglyceride,
age or blood pressure between the three groups (Table 1). The
differences in body mass index were not significant.
Figure 1 and Table 2 show the plasma glucose and serum
insulin concentrations during the OGTT in the three groups.
The increase in fasting plasma glucose levels as glucose toler-
ance deteriorated from IGT to DM was not significant, but the
difference between the DM group and the NGT group did
reach statistical significance (
 
P <
 
 0.01). After the glucose load,
both the plasma glucose and the serum insulin concentrations
increased in each group. Plasma glucose levels were signifi-
cantly higher in the IGT and the DM groups than in the NGT
group at 30, 60 and 120 min after glucose loading (
 
P <
 
 0.01).
The concentrations were not different between the IGT group
and the DM group at 30 min, but were significantly higher in
the DM group than in the IGT group at both 60 and 120 min
(
 
P <
 
 0.01). Fasting serum insulin concentrations were not
significantly different between the three groups and increased
significantly in each group after the glucose load. In the NGT
group, serum insulin concentrations peaked at 60 min, and
then decreased. In contrast, they continued to increase until
120 min after the glucose load in the IGT and DM groups.
FIGURE 1 Blood glucose, insulin, thioredoxin and 8-hydroxy-2′-deoxyguanosine (8-OHdG) concentrations during an oral glucose tolerance test in 
subjects with normal glucose tolerance (NGT,  ), impaired glucose tolerance (IGT, ×) and diabetes (∆). *P < 0.01 vs. NGT; †P < 0.05 vs. IGT; 
††P < 0.01 vs. IGT. 
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Serum insulin concentrations at 60 min in the NGT group
were the highest in the three groups (
 
P <
 
 0.01) and at 120 min
were the lowest (
 
P <
 
 0.01). There was no difference in the
insulin concentrations between the IGT and DM groups at
60 min or 120 min. Serum concentrations of TRX gradually
decreased after oral glucose loading in each group (
 
P <
 
 0.05 vs.
fasting; Fig. 1). Concentrations of 8-OHdG were similar in all
three groups, both fasting and at 30 min, and did not change
from fasting to 30 min in any group. 8-OHdG concentrations
decreased in the NGT and DM groups from 30 to 60 min (
 
P <
 
0.01). There were no significant changes in the IGT group.
The insulinogenic index was highest in the NGT group
and lowest in the DM group (NGT 0.904 
 
±
 
 0.511,  IGT
0.605 
 
±
 
 0.435, DM 0.376 
 
± 
 
0.256; 
 
P
 
 = 0.02 NGT vs. DM).
In the combined cohort, the insulinogenic index correlated
with the change in TRX during oral glucose loading (
 
∆
 
TRX)
(
 
r =
 
 0.34, 
 
P
 
 < 0.05) (Fig. 2). However, there was no relation-
ship with the change in 8-OHdG concentrations from fasting
to 30 min (
 
∆
 
8-OHdG).
 
Discussion
 
There is widespread agreement that diabetes increases the risk
of cardiovascular disease [2,3,18–21]. The mechanism of this
increased risk is controversial [3,18–22], but hyperglycaemia
may play an important role in patients with diabetes and IGT
[22,23]. Although hyperglycaemia is clearly related to diabetic
microvascular complications [22], its contribution to the
increased risk of atherosclerosis in Type 2 diabetes remains
controversial. Type 2 diabetes and IGT are commonly associated
with other risk factors, such as dyslipidaemia, hypertension
and obesity [3,18–22,24]. All of these factors may contribute
to the occurrence of cardiovascular disease in patients with
diabetes and IGT.
Failure of insulin secretion in patients with Type 2 diabetes
and IGT is characterized by decreased first-phase glucose-
induced insulin secretion, delayed hyperinsulinaemia and
Table 2 Concentrations of measured variables during oral glucose tolerance test
Fasting 30 min 60 min 120 min
Glucose (mmol/l) NGT 4.9 ± 0.4 8.6 ± 1.4** 5.9 ± 1.0** 4.3 ± 1.8
IGT 5.4 ± 0.4 9.9 ± 1.6** 10.9 ± 2.3** 9.6 ± 0.8**
DM 6.2 ± 0.7 11.6 ± 1.6** 13.5 ± 1.3** 11.2 ± 3.1**
Insulin (µU/ml) NGT 6.1 ± 2.2 65.1 ± 45.4** 105.2 ± 93.1** 42.3 ± 26.5**
IGT 7.9 ± 4.5 58.3 ± 46.8** 73.7 ± 39.1** 89.1 ± 37.6**
DM 11.1 ± 5.6 44.3 ± 20.9** 68.2 ± 28.2** 98.3 ± 67.2**
Thioredoxin (ng/ml) NGT 64.0 ± 19.9 59.1 ± 19.2* 48.5 ± 17.4** 38.7 ± 17.8**
IGT 67.9 ± 29.8 59.6 ± 26.3* 53.6 ± 28.5** 39.7 ± 19.9**
DM 70.0 ± 19.9 59.5 ± 27.6* 43.4 ± 16.8** 30.4 ± 14.6**
8-OHdG (ng/mL) NGT 0.44 ± 0.13 0.46 ± 0.11 0.35 ± 0.13** 0.36 ± 0.11**
IGT 0.35 ± 0.11 0.40 ± 0.13* 0.41 ± 0.11* 0.37 ± 0.16
DM 0.37 ± 0.07 0.44 ± 0.09* 0.28 ± 0.07** 0.29 ± 0.07**
*P < 0.05 vs. fasting; **P < 0.01 vs. fasting.
DM, Diabetes mellitus; IGT, impaired glucose tolerance; NGT, normal glucose tolerance.
FIGURE 2 Correlation between insulinogenic index and the change in 
thioredoxin from 0 to 30 min, and the relation between the insulinogenic 
index and the change in 8-hydroxy-2′-deoxyguanosine (8-OHdG) from 
0 to 30 min. I.I., Insulinogenic index; ∆thioredoxin, the change in 
thioredoxin; ∆8-OHdG, the change in 8-OHdG.  , Normal glucose 
tolerance; ∆, impaired glucose tolerance;  , diabetes. DIABETICMedicine Acute oxidative stress in hyperglycaemia • Y. Miyazaki et al.
© 2007 The Authors.
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the late development of failure of insulin synthesis [25–29].
In the present study, the peak in the glucose concentration
was 60 min after glucose loading in each group. In contrast,
although the peak of insulin concentration was 60 min after
glucose loading in the NGT group, the peak was at 120 min in
the DM and IGT groups. These findings suggested that insulin
secretion in response to oral glucose loading was already
impaired in the DM and the IGT group.
In the present study, oral glucose loading decreased serum
TRX concentrations. Thioredoxins are critical for redox regu-
lation of protein function and signalling via thiol redox control
[30]. TRX is induced by stress, and protects cells from various
types of stress, such as viral infection. TRX is not only a
scavenger of free reactive oxygen species but also regulates
the activity of various intracellular molecules, including trans-
cription factors such as nuclear factor-κB, activator protein 1,
myb, redox factor 1 and mitogen-activated kinase [31]. Thus,
cytosolic mammalian TRX has numerous functions in the
defence against oxidative stress, control of growth and apop-
tosis [32]. TRX and the redox system it modulates have an
important role in cellular defence against cytotoxicity caused
by reactive oxygen species. In the present study, we could not
show a relationship between the insulinogenic index and TRX
or 8-OHdG concentrations. However, there was a correlation
between the change in TRX concentrations after the oral
glucose loading and the insulinogenic index (Fig. 2). The changes
in glucose concentrations from fasting to 30 min after glucose
loading are the largest changes after the glucose load. Thus,
the concentrations of 8-OHdG increased 30 min after glucose
loading, and increased oxidative stress may affect the TRX
concentrations. The increased TRX is used to protect the cell
against oxidative stress. Therefore, both released extracellular
TRX and 8-OHdG concentrations decrease 60 min after
glucose loading [32]. The present study demonstrates that
hyperglycaemia after a glucose load may affect the cellular
antioxidant system in humans.
Glucose is the primary fuel and regulator of pancreatic islet
B-cell function. The primary function of insulin is to maintain
blood glucose concentrations in the normal range. However,
chronic hyperglycaemia impairs glucose-induced insulin
secretion and insulin gene expression [33]. One of the potential
mechanisms is oxidative stress, because glucose is able to
generate reactive oxygen species [4–7], which have adverse
effects on islet function [34–37]. The augmented reactive
oxygen species generation produced by exposure to elevated
glucose may play an important role in the diminished activity of
B-cells [38,39]. Although the pathogenesis of Type 2 diabetes
is multifactorial, B-cell functional abnormalities are present at
a very early stage of development of the disease [40,41]. It is
well known that B-cell dysfunction is observed even in patients
with IGT, as shown in the present study. Our findings suggest
that increased reactive oxygen species induced by postprandial
hyperglycaemia may affect B-cell function. Consequently,
insulin secretion in response to blood glucose may become
impaired. In the present study, 8-OHdG, a marker of oxidative
stress, increased after glucose loading, but TRX, a marker of
cellular redox state, decreased. There was a significant relation-
ship between TRX concentrations and insulinogenic index,
a marker of insulin secretory activity of B-cells. Thus, the
augmented reactive oxygen species production may reduce
cellular antioxidant defences. This may affect the B-cell and
result in impairment of insulin secretion.
A variety of mechanisms may generate reactive oxygen
species during acute hyperglycaemia [42–44]. These include
autoxidation, non-enzymatic glycation of proteins due to
extended exposure to hyperglycaemia, metabolism of glucose
via aldose reductase with changes in sorbitol-myoinositol
concentrations and the increased de novo synthesis of diacylg-
lycerol from glycolytic intermediates and subsequent activation
of the protein kinase C pathway [43,44]. However, non-
enzymatic glycation processes do not account for the rapid
increase of oxidative products in response to acute hypergly-
caemia, because glycation processes occur slowly over days to
weeks [45].
Our results suggest that acute hyperglycaemia produces
reactive oxygen species, and that the increase in reactive
oxygen species affects cellular antioxidant defences. In animal
models, antioxidant treatment protects against the onset of
diabetes [46]. In addition, acarbose effectively reduced the risk
of development of diabetes in patients with IGT [47]. Since this
α-glucosidase inhibitor reduces postprandial hyperglycaemia,
protection of B-cells from reactive oxygen species after post-
prandial hyperglycaemia could be a possible mechanism by
which acarbose prevents progression to diabetes mellitus.
These previous reports support our findings.
It is possible that TRX is induced by hyperinsulinaemia or
dyslipidaemia in IGT or diabetes and thus alters the insulino-
genic index. Thus, further studies are needed to clarify the role
of hyperinsulinaemia and dyslipidaemia in insulin secretion in
humans.
In conclusion, acute hyperglycaemia in response to oral
glucose loading generates reactive oxygen species, which may
affect the cellular redox state. Thus, postprandial hypergly-
caemia reduces pancreatic B-cell function, and results in impair-
ment of insulin secretion. These findings strongly suggest that
repeated postprandial hyperglycaemia may play an important
role in the development and progression of diabetes mellitus.
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